{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:03Z","timestamp":1775872263967,"version":"3.50.1"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP Rep"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Angiotensin II receptor blockers (ARBs) are commonly used for hypertension but are contraindicated in pregnancy due to risks of oligohydramnios, renal dysgenesis, and pulmonary hypoplasia from suppression of the fetal renin\u2013angiotensin system. Olmesartan, a frequently prescribed ARB, has a longer receptor binding half-life and higher affinity than other ARBs, producing more potent and sustained antihypertensive effects. Emerging evidence suggests that stopping ARBs during pregnancy may allow recovery of amniotic fluid and renal function.<\/jats:p>\n                  <jats:p>A 30-year-old primigravida with chronic hypertension presented at 24 weeks' gestation while taking olmesartan. Ultrasound revealed anhydramnios with a normal-appearing fetal genitourinary tract. Olmesartan was discontinued and replaced with labetalol. Within 2 weeks, the amniotic fluid index normalized, and subsequent ultrasounds showed sustained recovery. At 34 weeks, she delivered a viable male infant with reassuring renal function and only mild, improving calyceal dilation on postnatal ultrasound.<\/jats:p>\n                  <jats:p>This is, to our knowledge, the first reported case of reversible anhydramnios associated with first- and second-trimester olmesartan exposure. The favorable outcome highlights the potential for reversibility of ARB-related fetopathy with timely cessation. Clinicians should consider serial ultrasound monitoring before recommending termination, as early drug withdrawal may restore amniotic fluid and support normal neonatal outcomes.<\/jats:p>","DOI":"10.1055\/a-2816-0125","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:41:19Z","timestamp":1771548079000},"page":"e54-e58","source":"Crossref","is-referenced-by-count":1,"title":["Rapid Normalization of Amniotic Fluid Index Following Discontinuation of Olmesartan: A Case Report"],"prefix":"10.1055","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-2591","authenticated-orcid":false,"given":"Annika","family":"Van Oosbree","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Medical University of South Carolina; Charleston, South Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese","family":"Larson","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Medical University of South Carolina; Charleston, South Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Conley","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Medical University of South Carolina; Charleston, South Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Bridges","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical University of South Carolina; Charleston, South Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Argoti","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Medical University of South Carolina; Charleston, South Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Mari","sequence":"additional","affiliation":[{"name":"Division of Maternal-Fetal Medicine, Baylor University; Houston, Texas, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"05","key":"ref1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/hr.2015.12","article-title":"Outcomes of 83 fetuses exposed to angiotensin receptor blockers during the second or third trimesters: a literature review","volume":"38","author":"C Shimada","year":"2015","journal-title":"Hypertens Res"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1476-5381.1996.tb15999.x","article-title":"Comparison of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition in pregnant sheep during late gestation","volume":"119","author":"A J Forhead","year":"1996","journal-title":"Br J Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"A33","DOI":"10.1016\/S0149-2918(04)90144-0","article-title":"Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials","volume":"26","author":"K O Stumpe","year":"2004","journal-title":"Clin Ther"},{"issue":"09","key":"ref4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200868090-00003","article-title":"Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension","volume":"68","author":"D H Smith","year":"2008","journal-title":"Drugs"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1472-8206.2007.00464.x","article-title":"Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies","volume":"21","author":"F Zannad","year":"2007","journal-title":"Fundam Clin Pharmacol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/AOG.0000000000003020","article-title":"ACOG practice bulletin no. 203: chronic hypertension in pregnancy","volume":"133","author":"American College of Obstetricians and Gynecologists' Committee on Practice Bulletins\u2014Obstetrics","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00467-013-2749-4","article-title":"Fetal renin-angiotensin-system blockade syndrome: renal lesions","volume":"29","author":"C Plazanet","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"ref8","first-page":"2382031","article-title":"Reversible fetal renal impairment following angiotensin receptor blocking treatment during third trimester of pregnancy: case report and review of the literature","volume":"2016","author":"T Saar","year":"2016","journal-title":"Case Rep Obstet Gynecol"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/s-2007-994324","article-title":"Reversible oligohydramnios in a pregnancy with angiotensin-converting enzyme inhibitor exposure","volume":"14","author":"C A Chisholm","year":"1997","journal-title":"Am J Perinatol"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.jp.7210766","article-title":"Pregnancy with prolonged fetal exposure to an angiotensin-converting enzyme inhibitor","volume":"22","author":"P R Muller","year":"2002","journal-title":"J Perinatol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"e24304","DOI":"10.1097\/MD.0000000000024304","article-title":"Use of angiotensin II receptor blocker during pregnancy: a case report","volume":"100","author":"Q Wei","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.reprotox.2010.01.010","article-title":"Reversible fetal renal failure after maternal treatment with Candesartan: a case report","volume":"29","author":"P S Munk","year":"2010","journal-title":"Reprod Toxicol"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.jp.7210871","article-title":"Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist","volume":"23","author":"C Pietrement","year":"2003","journal-title":"J Perinatol"},{"issue":"08","key":"ref14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/bdra.20047","article-title":"Fetal toxicity of valsartan and possible reversible adverse side effects","volume":"70","author":"N Berkane","year":"2004","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000187942.09107.08","volume-title":"Utero Losartan Withdrawal and Subsequent Development of Fetal Inferior Vena Cava Thrombosis","author":"J N Bakkum","year":"2006"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2006-947162","article-title":"Gestational therapy with an angiotensin II receptor antagonist and transient renal failure in a premature infant","volume":"23","author":"J K Bass","year":"2006","journal-title":"Am J Perinatol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00467-007-0618-8","article-title":"Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker","volume":"23","author":"C Celentano","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1345\/aph.1A013","article-title":"Fatal fetal outcome with the combined use of valsartan and atenolol","volume":"35","author":"G G Briggs","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00467-006-0162-y","article-title":"Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan","volume":"21","author":"G D Simonetti","year":"2006","journal-title":"Pediatr Nephrol"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/pr.112.007278","article-title":"A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists","volume":"65","author":"M C Michel","year":"2013","journal-title":"Pharmacol Rev"},{"issue":"06","key":"ref21","first-page":"2067","article-title":"Early expression of all the components of the renin-angiotensin-system in human development","volume":"149","author":"S Sch\u00fctz","year":"1996","journal-title":"Am J Pathol"},{"issue":"03","key":"ref22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.placenta.2010.12.006","article-title":"Molecular characterization of renin-angiotensin system components in human intrauterine tissues and fetal membranes from vaginal delivery and cesarean section","volume":"32","author":"F Z Marques","year":"2011","journal-title":"Placenta"}],"container-title":["American Journal of Perinatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2816-0125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:16:00Z","timestamp":1773105360000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2816-0125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2816-0125","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2157-6998","2157-7005"],"issn-type":[{"value":"2157-6998","type":"print"},{"value":"2157-7005","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,19]]},"published":{"date-parts":[[2026,1]]}}}